Q-omics provides the consensus-scored COX10 profile across patient tissues and cancer cell-line models. COX10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, COX10 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, COX10 RNA expression shows 18,668 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, THCA, and ACC as cancer lineages where COX10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX10 survival associations across molecular data types. COX10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX10 RNA expression–survival associations across cancer types. High COX10 expression shows unfavorable associations in KICH, LIHC and ACC, but favorable associations in BRCA, READ and STAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for COX10 RNA expression.
This table summarizes COX10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for COX10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX10 shows lower tumor expression in THCA, KICH, COAD and KIRC and higher tumor expression in LUSC and KIRP. The THCA box plot shows higher COX10 RNA expression in normal versus tumor tissue (log2 FC = −1.118, t-test p < 0.001).
This table shows molecular features associated with COX10 in patient tissues and cancer cell lines. In patient samples, COX10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, COX10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
